Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Changes
... 15 Artifacts Summary
.... 15.1 AbsenceOfExposureDefinition
.... 15.2 Adaptation
.... 15.3 BaselineMeasureEvidence
.... 15.4 BaselineMeasureReport
.... 15.5 BaselineVariablesList
.... 15.6 BookCitation
.... 15.7 BookPartCitation
.... 15.8 CertaintyOfEvidence
.... 15.9 Classification
.... 15.10 CohortDefinition
.... 15.11 Comment
.... 15.12 ComparativeBaselineMeasureEvidence
.... 15.13 ComparativeEvidence
.... 15.14 ComparativeEvidenceReport
.... 15.15 ComparativeEvidenceReportExpanded
.... 15.16 ComparativeEvidenceReportSubject
.... 15.17 ComparativeEvidenceSynthesisReport
.... 15.18 ComparativeParticipantFlowEvidence
.... 15.19 ComparatorGroup
.... 15.20 ComparatorOnlyEvidence
.... 15.21 Comparison
.... 15.22 CompositeRating
.... 15.23 ConceptualCohortDefinition
.... 15.24 ConceptualComparatorDefinition
.... 15.25 ConceptualExposureDefinition
.... 15.26 DatabaseCitation
.... 15.27 DatabaseEntryCitation
.... 15.28 DatasetCitation
.... 15.29 DateAsRating
.... 15.30 DichotomousIntendedOutcome
.... 15.31 EndpointAnalysisPlan
.... 15.32 EvidenceAssessment
.... 15.33 EvidenceList
.... 15.34 EvidenceReport
.... 15.35 EvidenceReportPackage
.... 15.36 EvidenceReportSubject
.... 15.37 EvidenceSynthesisEvidence
.... 15.38 ExposureGroup
.... 15.39 GroupAssignment
.... 15.40 GroupR6
.... 15.41 Guideline
.... 15.42 InterventionOnlyEvidence
.... 15.43 JournalArticleCitation
.... 15.44 M11Report
.... 15.45 MetaanalysisEligibilityCriteria
.... 15.46 MetaanalysisOutcomeDefinition
.... 15.47 MetaanalysisStudyGroup
.... 15.48 NetEffectContribution
.... 15.49 NetEffectContributionList
.... 15.50 NetEffectContributions
.... 15.51 NetEffectEstimate
.... 15.52 NonComparativeEvidence
.... 15.53 OutcomeDefinition
.... 15.54 OutcomeImportance
.... 15.55 OutcomeList
.... 15.56 OutcomeMeasureReport
.... 15.57 OutcomeVariablesList
.... 15.58 ParticipantFlowEvidence
.... 15.59 ParticipantFlowEvidenceVariable
.... 15.60 ParticipantFlowReasonEvidenceVariable
.... 15.61 ParticipantFlowReport
.... 15.62 ParticipantFlowVariablesList
.... 15.63 PICOSpecification
.... 15.64 PICOTaggedComposition
.... 15.65 PICOTaggedEvidence
.... 15.66 PreprintCitation
.... 15.67 Rating
.... 15.68 Recommendation
.... 15.69 RecommendationAction
.... 15.70 RecommendationEligibilityCriteria
.... 15.71 RecommendationJustification
.... 15.72 RecommendationPlan
.... 15.73 RecommendationRating
.... 15.74 ResearchStudyDataDictionary
.... 15.75 ResearchStudySite
.... 15.76 ResearchStudySupport
.... 15.77 RiskOfBias
.... 15.78 SearchResults
.... 15.79 SearchStrategy
.... 15.80 SingleStudyEvidence
.... 15.81 SoaPlanDefinition
.... 15.82 SoftwareCitation
.... 15.83 StatisticModel
.... 15.84 StudyComponent
.... 15.85 StudyDesign
.... 15.86 StudyEligibilityCriteria
.... 15.87 StudyGroup
.... 15.88 StudyRegistryRecord
.... 15.89 SummaryOfFindings
.... 15.90 SummaryOfNetEffect
.... 15.91 SystematicReview
.... 15.92 SystematicReviewEligibilityCriteria
.... 15.93 SystematicReviewExcludedStudies
.... 15.94 SystematicReviewIncludedStudies
.... 15.95 VariableDefinition
.... 15.96 WebPageCitation
.... 15.97 ArtifactAssessmentCompared
.... 15.98 ArtifactAssessmentDateAsRating
.... 15.99 ArtifactPublicationStatus
.... 15.100 ArtifactRecorder
.... 15.101 CharacteristicTiming
.... 15.102 CiteAs
.... 15.103 EvidenceVariableHandlingDetail
.... 15.104 GuidelineRegistration
.... 15.105 NumberAnalyzed
.... 15.106 RelatesToClassifier
.... 15.107 RelatesToWithQuotation
.... 15.108 RelativeOutcomeImportance
.... 15.109 RelevantForAutomatedMatching
.... 15.110 ResearchStudyExcludedStudy
.... 15.111 ResearchStudyIncludedStudy
.... 15.112 ResearchStudyIsLowInterventionTrial
.... 15.113 ResearchStudyIsRareDisease
.... 15.114 ResearchStudyNumberOfStudiesIdentified
.... 15.115 ResearchStudyNumberOfStudiesIncluded
.... 15.116 ResearchStudySaeReportingMethod
.... 15.117 ResearchStudySearchStrategy
.... 15.118 ResearchStudySponsorConfidentialityStatement
.... 15.119 ResearchStudyStudyAmendment
.... 15.120 ResearchStudySystematicReviewEligibilityCriteria
.... 15.121 StatisticModelExpression
.... 15.122 StatisticModelIncludeIf
.... 15.123 Desirability Codes Value Set
.... 15.124 EBMonFHIR Profile Name Value Set
.... 15.125 Evidence Rating System Classifier Codes Value Set
.... 15.126 PICO Classification Value Set
.... 15.127 Recommendation Justification Classifier Codes Value Set
.... 15.128 Research Study Document Types Value Set
.... 15.129 ResearchStudy Classifier Value Set
.... 15.130 Search Strategy Characteristic Value Set
.... 15.131 Desirability Code System
.... 15.132 EBMonFHIR Profile Name Code System
.... 15.133 Evidence Rating System Classifier Code System
.... 15.134 Research Study Document Types Code System
.... 15.135 Search Strategy Characteristic Code System
.... 15.136 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 15.137 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.138 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 15.139 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 15.140 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 15.141 179899
.... 15.142 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 15.143 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 15.144 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 15.145 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 15.146 19967827 Wonder woman was Argentine and her real name was Evita.
.... 15.147 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 15.148 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 15.149 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 15.150 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 15.151 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 15.152 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 15.153 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 15.154 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 15.155 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 15.156 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 15.157 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 15.158 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 15.159 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 15.160 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 15.161 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 15.162 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 15.163 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 15.164 27979893 6. Glycemic Targets.
.... 15.165 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 15.166 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 15.167 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 15.168 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 15.169 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 15.170 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 15.171 30467172 Finding my inner Wonder Woman.
.... 15.172 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.173 34871555 What Can Wonder Woman Teach Radiologists?
.... 15.174 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 15.175 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 15.176 367832
.... 15.177 367833
.... 15.178 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 15.179 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 15.180 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 15.181 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 15.182 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 15.183 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.184 Add-on Amlodipine at 6 weeks
.... 15.185 Adults with diabetes mellitus type 2
.... 15.186 Adults with type 2 diabetes and CVD and CKD
.... 15.187 Adults with type 2 diabetes and established CVD (but no CKD)
.... 15.188 Adverse event free and hypertension control
.... 15.189 Adverse event free and hypertension control at 12 weeks
.... 15.190 Adverse Events Report for NCT03421379
.... 15.191 Adverse Events Report for NCT03640312
.... 15.192 Age
.... 15.193 Age with comparator
.... 15.194 Age with intervention
.... 15.195 Aircraft Type
.... 15.196 Aircraft Type with comparator
.... 15.197 Aircraft Type with intervention
.... 15.198 Altitude
.... 15.199 Altitude comparing intervention vs. comparator
.... 15.200 Altitude for enrolled group
.... 15.201 Altitude for screened group
.... 15.202 Altitude with comparator
.... 15.203 Altitude with intervention
.... 15.204 Analyzed Group in PARACHUTE Trial
.... 15.205 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 15.206 Baseline Characteristics Report for NCT03421379
.... 15.207 Baseline Characteristics Report for NCT03640312
.... 15.208 Baseline Characteristics Report for QUARTET Trial
.... 15.209 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.210 Baseline Measures List for PARACHUTE Trial
.... 15.211 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 15.212 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 15.213 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 15.214 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 15.215 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.216 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 15.217 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.218 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 15.219 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 15.220 Candesartan 8 mg once daily
.... 15.221 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.222 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 15.223 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.224 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.225 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.226 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.227 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 15.228 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 15.229 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.230 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.231 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.232 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.233 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.234 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.235 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.236 Citation for EBMonFHIR Implementation Guide
.... 15.237 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 15.238 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 15.239 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.240 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 15.241 Comparative Evidence Report for QUARTET USA Trial
.... 15.242 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.243 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 15.244 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.245 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 15.246 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.247 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.248 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.249 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.250 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 15.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 15.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 15.254 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 15.255 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 15.256 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 15.257 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 15.258 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 15.259 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 15.260 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 15.261 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 15.262 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 15.263 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 15.264 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 15.265 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 15.266 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.267 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.268 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.269 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.270 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 15.271 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.272 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 15.273 ComparatorDefinition: Standard care
.... 15.274 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.275 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.276 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 15.277 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 15.278 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.279 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.280 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 15.281 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.282 Composite Rating of FOI 153881 for Project FOI 112280
.... 15.283 Computable_Publishing_LLC
.... 15.284 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 15.285 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.286 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.287 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.288 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 15.289 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 15.290 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 15.291 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 15.292 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 15.293 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 15.294 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 15.295 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 15.296 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 15.297 ConceptualCohortDefinition: Nonfatal stroke
.... 15.298 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 15.299 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 15.300 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 15.301 ConceptualCohortDefinition: Severe obesity
.... 15.302 ConceptualCohortDefinition: T1DM or T2DM
.... 15.303 ConceptualCohortDefinition: T1DM-specific criteria
.... 15.304 ConceptualCohortDefinition: T2DM-specific criteria
.... 15.305 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 15.306 ConceptualCohortDefinition_Cardiovascular_event
.... 15.307 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.308 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 15.309 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.310 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 15.311 COVID_19PneumoniaHospitalizedAdult
.... 15.312 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.313 CTIS2024-516402-32-00 Eligibility Criteria
.... 15.314 CTIS2024-516402-32-00 Primary Outcome 1
.... 15.315 CTIS2024-516402-32-00 Secondary Outcome 1
.... 15.316 CTIS2024-516402-32-00 Secondary Outcome 2
.... 15.317 CTIS2024-516402-32-00 Secondary Outcome 3
.... 15.318 CTIS2024-516402-32-00 Secondary Outcome 4
.... 15.319 CTIS2024-516402-32-00 Secondary Outcome 5
.... 15.320 CTIS2024-516402-32-00 Secondary Outcome 6
.... 15.321 CTIS2024-516402-32-00 Secondary Outcome 7
.... 15.322 CTIS2024-516402-32-00 Secondary Outcome 8
.... 15.323 DatabaseCitation: Citation for FEvIR Platform
.... 15.324 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.325 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 15.326 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 15.327 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 15.328 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 15.329 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 15.330 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 15.331 declined randomization in PARACHUTE Study
.... 15.332 deemed unsuitable by investigator in PARACHUTE Trial
.... 15.333 Delany-Moretlwe 2022 clinical trial
.... 15.334 Diabetes treatment medication
.... 15.335 Diastolic blood pressure at 12 weeks
.... 15.336 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure
.... 15.337 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 15.338 DichotomousIntendedOutcome: New onset depression
.... 15.339 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke
.... 15.340 DichotomousIntendedOutcome: Remission of diabetes
.... 15.341 DichotomousIntendedOutcome: Treatment with opioids
.... 15.342 DIO: Mortality
.... 15.343 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 15.344 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 15.345 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 15.346 Eligibility criteria for NMA_Diabetes
.... 15.347 Eligibility Criteria for QUARTET USA Trial
.... 15.348 Enrolled Group for QUARTET USA Trial
.... 15.349 Enrolled Group PARACHUTE Trial
.... 15.350 Ethnic Group
.... 15.351 Ethnic Group with comparator
.... 15.352 Ethnic Group with intervention
.... 15.353 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 15.354 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.355 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.356 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 15.357 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 15.358 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.359 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.360 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 15.361 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.362 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.363 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.364 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.365 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.366 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.367 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.368 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 15.369 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.370 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.371 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.372 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 15.373 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.374 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.375 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 15.376 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 15.377 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 15.378 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 15.379 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.380 EvidenceReportSectionCode Value Set
.... 15.381 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.382 EvidenceVariable Handling Extension Value Set
.... 15.383 EvidenceVariable: case_id
.... 15.384 EvidenceVariable: Patient id
.... 15.385 EvidenceVariable: Time of measurement
.... 15.386 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 15.387 Excluded from PARACHUTE Study
.... 15.388 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 15.389 ExposureVariable: Age (as continuous variable)
.... 15.390 ExposureVariable: Body Mass Index (as continuous variable)
.... 15.391 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 15.392 ExposureVariable: pht013093.v1.p1 RACE
.... 15.393 ExposureVariable: pht013093.v1.p1 SEX
.... 15.394 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 15.395 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 15.396 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 15.397 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 15.398 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 15.399 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 15.400 ExposureVariable: pht013094.v1.p1 Source_Type
.... 15.401 Family History of Parachute Use
.... 15.402 Family History of Parachute Use with comparator
.... 15.403 Family History of Parachute Use with intervention
.... 15.404 Frequent Flier
.... 15.405 Frequent Flier with comparator
.... 15.406 Frequent Flier with intervention
.... 15.407 GLP-1 RA Group in Adults with type 2 diabetes
.... 15.408 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 15.409 Glucagon Hydrochloride Solution (Active Comparator)
.... 15.410 Glucagon Nasal Powder (Experimental)
.... 15.411 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 15.412 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 15.413 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 15.414 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 15.415 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 15.416 GroupAssignment: GLP-1 RA vs. Standard care
.... 15.417 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 15.418 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 15.419 GroupAssignment: Non Participants vs. Enrolled Participants
.... 15.420 GroupAssignment: Quadpill vs. Candesartan
.... 15.421 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 15.422 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 15.423 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 15.424 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 15.425 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 15.426 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.427 Health Survey Score Total
.... 15.428 Health Survey Score Total comparing intervention vs. comparator
.... 15.429 Health Survey Score Total with comparator
.... 15.430 Health Survey Score Total with intervention
.... 15.431 Health Survey Score-Mental Health Subscore
.... 15.432 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 15.433 Health Survey Score-Mental Health Subscore with comparator
.... 15.434 Health Survey Score-Mental Health Subscore with intervention
.... 15.435 Health Survey Score-Physical Health Subscore
.... 15.436 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 15.437 Health Survey Score-Physical Health Subscore with comparator
.... 15.438 Health Survey Score-Physical Health Subscore with intervention
.... 15.439 Health-related Quality of Life (NCT03640312)
.... 15.440 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 15.441 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.442 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.443 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 15.444 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 15.445 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 15.446 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.447 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.448 Height
.... 15.449 Height with comparator
.... 15.450 Height with intervention
.... 15.451 High Blood Pressure Medication Value Set
.... 15.452 History of Acrophobia
.... 15.453 History of Acrophobia with comparator
.... 15.454 History of Acrophobia with intervention
.... 15.455 History of Broken Bones
.... 15.456 History of Broken Bones with comparator
.... 15.457 History of Broken Bones with intervention
.... 15.458 History of Parachute Use
.... 15.459 History of Parachute Use with comparator
.... 15.460 History of Parachute Use with intervention
.... 15.461 Hypertension Control at 12 weeks
.... 15.462 ICD-10-GM Terminale Codes
.... 15.463 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 15.464 Injury Severity Score 30 days after Impact with comparator
.... 15.465 Injury Severity Score 30 days after Impact with intervention
.... 15.466 Injury Severity Score on Impact comparing intervention vs. comparator
.... 15.467 Injury Severity Score on Impact with comparator
.... 15.468 Injury Severity Score on Impact with intervention
.... 15.469 International vs Domestic Flight
.... 15.470 International vs Domestic Flight with comparator
.... 15.471 International vs Domestic Flight with intervention
.... 15.472 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 15.473 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 15.474 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.475 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.476 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.477 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 15.478 Investigator
.... 15.479 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 15.480 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 15.481 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.482 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 15.483 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 15.484 Jumping from aircraft with empty backpack
.... 15.485 Jumping from aircraft with parachute
.... 15.486 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.487 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.488 M11 IGBJ Protocol Example Eligibility Criteria
.... 15.489 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 15.490 M11 Report Template Instructions
.... 15.491 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.492 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.493 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.494 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.495 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.496 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.497 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.498 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.499 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.500 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.501 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.502 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.503 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.504 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.505 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.506 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.507 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.508 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.509 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.510 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.511 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 15.512 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.513 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.514 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.515 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.516 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.517 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.518 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.519 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.520 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.521 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.522 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.523 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.524 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.525 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.526 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.527 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.528 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.529 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.530 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.531 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.532 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.533 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.534 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.535 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.536 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.537 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.538 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.539 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.540 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.541 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.542 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.543 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.544 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.545 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.546 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.547 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.548 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.549 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.550 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.551 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.552 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.553 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.554 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.555 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 15.556 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.557 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 15.558 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 15.559 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.560 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.561 Mean Change in Serum Creatinine (NCT03640312)
.... 15.562 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 15.563 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.564 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.565 Mean Change in Serum Potassium (NCT03640312)
.... 15.566 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 15.567 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.568 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.569 Mean Change in Serum Sodium (NCT03640312)
.... 15.570 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 15.571 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.572 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.573 Mean Diastolic Blood Pressure (NCT03640312)
.... 15.574 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.575 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.576 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.577 Mean Systolic Blood Pressure (NCT03640312)
.... 15.578 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 15.579 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.580 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.581 Median Age of Parachute Intervention Group
.... 15.582 Medication Adherence (NCT03640312)
.... 15.583 Medication Adherence at 12 weeks
.... 15.584 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 15.585 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.586 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.587 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.588 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.589 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 15.590 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 15.591 Mortality at 14 days
.... 15.592 NCT03421379 Eligibility Criteria
.... 15.593 NCT03640312 Eligibility Criteria
.... 15.594 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 15.595 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 15.596 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 15.597 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 15.598 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 15.599 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 15.600 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 15.601 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 15.602 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.603 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 15.604 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 15.605 NHANES LBXGLU Variable Definition Cohort Definition
.... 15.606 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 15.607 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 15.608 NHANES SEQN Respondent Sequence Number
.... 15.609 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 15.610 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 15.611 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 15.612 NT-proBNP Study Data Dictionary
.... 15.613 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 15.614 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 15.615 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 15.616 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.617 Organ support-free days
.... 15.618 Outcome Importance Rating 100 of All-cause mortality
.... 15.619 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 15.620 Outcome Importance Rating 5 of New onset depression
.... 15.621 Outcome Importance Rating 5 of Remission of diabetes
.... 15.622 Outcome Importance Rating 5 of Treatment with opioids
.... 15.623 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 15.624 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.625 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.626 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.627 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.628 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study)
.... 15.629 Outcome Importance Rating of Mortality for Bariatric Surgery Patients
.... 15.630 Outcome Measure List for QUARTET USA Trial
.... 15.631 Outcome Measure Report for QUARTET USA Trial
.... 15.632 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.633 Outcome Measures Report for NCT03421379
.... 15.634 Outcome Measures Report for NCT03640312
.... 15.635 Outcome Variables List for PARACHUTE Trial
.... 15.636 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 15.637 Outcome: Death or Major Traumatic Injury on Impact
.... 15.638 Outcome: Injury Severity Score 30 days after Impact
.... 15.639 Outcome: Injury Severity Score on Impact
.... 15.640 OutcomeDefinition: Injury Severity Score on Impact
.... 15.641 OutcomeDefinition: All-cause mortality
.... 15.642 OutcomeDefinition: All-cause mortality
.... 15.643 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 15.644 OutcomeDefinition: Body weight
.... 15.645 OutcomeDefinition: Body weight
.... 15.646 OutcomeDefinition: Cardiovascular mortality
.... 15.647 OutcomeDefinition: Cardiovascular mortality
.... 15.648 OutcomeDefinition: Diabetes in remission
.... 15.649 OutcomeDefinition: Diabetic ketoacidosis
.... 15.650 OutcomeDefinition: End-stage kidney disease
.... 15.651 OutcomeDefinition: End-stage kidney disease
.... 15.652 OutcomeDefinition: Genital infection
.... 15.653 OutcomeDefinition: HbA1c at 12 months
.... 15.654 OutcomeDefinition: HbA1c at 24 months
.... 15.655 OutcomeDefinition: HbA1c at 36 months
.... 15.656 OutcomeDefinition: HbA1c at 6 months
.... 15.657 OutcomeDefinition: HbA1c at 60 months
.... 15.658 OutcomeDefinition: Health-related quality of life
.... 15.659 OutcomeDefinition: Health-related quality of life
.... 15.660 OutcomeDefinition: Heart failure
.... 15.661 OutcomeDefinition: Heart failure
.... 15.662 OutcomeDefinition: Mortality at 14 days
.... 15.663 OutcomeDefinition: New onset depression
.... 15.664 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.665 OutcomeDefinition: Nonfatal myocardial infarction
.... 15.666 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 15.667 OutcomeDefinition: Nonfatal stroke
.... 15.668 OutcomeDefinition: Nonfatal stroke
.... 15.669 OutcomeDefinition: Serious hyperglycaemia
.... 15.670 OutcomeDefinition: Serious hyperglycaemia
.... 15.671 OutcomeDefinition: Severe gastrointestinal events
.... 15.672 OutcomeDefinition: Severe gastrointestinal events
.... 15.673 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 15.674 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.675 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 15.676 OutcomeVariable: HbA1c at 12 months
.... 15.677 OutcomeVariable: HbA1c at 24 months
.... 15.678 OutcomeVariable: HbA1c at 36 months
.... 15.679 OutcomeVariable: HbA1c at 6 months
.... 15.680 OutcomeVariable: HbA1c at 60 months
.... 15.681 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 15.682 OutcomeVariable: New onset depression
.... 15.683 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 15.684 OutcomeVariable: Remission of diabetes
.... 15.685 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 15.686 OutcomeVariable_Additional_GI_surgical_procedure
.... 15.687 OutcomeVariable_All_cause_mortality
.... 15.688 OutcomeVariable_Treatment_with_opioids
.... 15.689 PARACHUTE Trial baseline characteristics
.... 15.690 PARACHUTE Trial non participants
.... 15.691 PARACHUTE trial participant flow report
.... 15.692 PARACHUTE Trial Participants
.... 15.693 PARACHUTE Trial Participants assigned an empty backpack
.... 15.694 PARACHUTE trial participants assigned parachute
.... 15.695 PARACHUTE Trial Participants available for randomization
.... 15.696 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 15.697 PARACHUTE Trial Participants randomized into groups
.... 15.698 PARACHUTE Trial Participants randomized into groups for screened group
.... 15.699 PARACHUTE Trial Participants randomized into groups with comparator
.... 15.700 PARACHUTE Trial Participants randomized into groups with intervention
.... 15.701 PARACHUTE Trial Participants that completed 30 day follow up
.... 15.702 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 15.703 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 15.704 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 15.705 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 15.706 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 15.707 PARACHUTE Trial Participants that declined randomization
.... 15.708 PARACHUTE Trial Participants with no contact at 30 days
.... 15.709 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 15.710 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 15.711 PARACHUTE Trial Results
.... 15.712 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 15.713 Parachute vs Empty Backpack in PARACHUTE Trial
.... 15.714 Participant Flow Report for NCT03421379
.... 15.715 Participant Flow Report for NCT03640312
.... 15.716 Participant Flow Report for QUARTET USA Trial
.... 15.717 Participant Flow Variables List for PARACHUTE Trial
.... 15.718 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 15.719 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 15.720 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 15.721 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 15.722 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 15.723 ParticipantFlowMeasure: Exclusion from analysis
.... 15.724 ParticipantFlowMeasure: Inclusion in analysis
.... 15.725 Participants Excluded from PARACHUTE Study
.... 15.726 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 15.727 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 15.728 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.729 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.730 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.731 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 15.732 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.733 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.734 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 15.735 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 15.736 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 15.737 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.738 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.739 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 15.740 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 15.741 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.742 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.743 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 15.744 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.745 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.746 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.747 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.748 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.749 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.750 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.751 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.752 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 15.753 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 15.754 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 15.755 Placebo
.... 15.756 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.757 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.758 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 15.759 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 15.760 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 15.761 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.762 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.763 Proportion of Patients With Hypertension Control (NCT03640312)
.... 15.764 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 15.765 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 15.766 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 15.767 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 15.768 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 15.769 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 15.770 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.771 Quadpill once daily
.... 15.772 QUARTET USA Trial Control Group
.... 15.773 QUARTET USA Trial Quadpill group
.... 15.774 randomized into groups for PARACHUTE Trial
.... 15.775 Rate of Adverse Events of Special Interest (NCT03640312)
.... 15.776 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 15.777 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 15.778 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 15.779 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 15.780 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 15.781 Reasons for exclusion from QUARTET USA Trial
.... 15.782 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 15.783 Recommendation Justification Code System
.... 15.784 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 15.785 Recommendation: ADA Obesity Management Recommendation 8.16
.... 15.786 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 15.787 Recommendation: ADA Obesity Management Recommendation 8.17
.... 15.788 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 15.789 Remdesivir
.... 15.790 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 15.791 ResearchStudy Classifier Code System
.... 15.792 Results Section for NCT03421379
.... 15.793 Results Section for NCT03640312
.... 15.794 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 15.795 Risk of Bias Assessment of PARACHUTE trial
.... 15.796 Risk Of Bias Type Value Set
.... 15.797 Screened Group PARACHUTE Trial
.... 15.798 Search Strategy for NMA_Diabetes
.... 15.799 SearchResults: PubMed search for Wonder Woman
.... 15.800 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 15.801 SearchStrategy: PubMed search for Wonder Woman
.... 15.802 Sex
.... 15.803 Sex with comparator
.... 15.804 Sex with intervention
.... 15.805 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 15.806 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 15.807 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 15.808 Spanish or English Value Set
.... 15.809 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 15.810 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 15.811 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 15.812 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 15.813 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 15.814 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 15.815 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 15.816 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 15.817 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 15.818 Summary of Findings - QUARTET USA Trial
.... 15.819 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 15.820 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 15.821 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 15.822 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 15.823 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.824 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.825 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 15.826 Systolic blood pressure at 12 weeks
.... 15.827 Time to integration of results in a recommendation
.... 15.828 VariableDefinition: Comparator
.... 15.829 VariableDefinition: Condition(s)
.... 15.830 VariableDefinition: Date of birth
.... 15.831 VariableDefinition: Date of measurement
.... 15.832 VariableDefinition: Gender
.... 15.833 VariableDefinition: NTproBNP
.... 15.834 VariableDefinition: Unit
.... 15.835 Velocity
.... 15.836 Velocity comparing intervention vs. comparator
.... 15.837 Velocity for enrolled group
.... 15.838 Velocity for non participant group
.... 15.839 Velocity with comparator
.... 15.840 Velocity with intervention
.... 15.841 WebPageCitation: A HEvKA Update Summary
.... 15.842 Weight
.... 15.843 Weight with comparator
.... 15.844 Weight with intervention